Drug intelligence / Profile preview

ranevetmab

Development stage: Preclinical
Lead developer: Nexvet Biopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

**Ranevetmab** is a caninized monoclonal antibody that targets nerve growth factor (NGF/NGFB) to alleviate pain associated with osteoarthritis in dogs. Developed by Nexvet Biopharma, it demonstrated significant improvements in pain scores, mobility, and function in pivotal and pilot field studies involving hundreds of dogs, using monthly subcutaneous or intravenous injections, with a favorable safety profile and no major adverse events.[2][4][7][9]

Targets

NGF (Nerve growth factor)

Beyond the preview

Go deeper on ranevetmab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ranevetmab.

Explore the full profile